99971-84-3

Basic information

• Product Name: 4,6-dichloro-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine
• Synonyms: 4,6-dichloro-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine;4,6-dichloro-1-phenylpyrazolo[3,4-d]pyrimidine
• CAS NO: 99971-84-3
• Molecular Formula: C₁₁H₆Cl₂N₄
• Molecular Weight: 265.09814
• Mol File: 99971-84-3.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4,6-dichloro-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-dichloro-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine(99971-84-3)
• EPA Substance Registry System: 4,6-dichloro-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine(99971-84-3)

Safety Data

• Hazardous Substances Data: 99971-84-3(Hazardous Substances Data)

Usage

General Description

4,6-dichloro-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine, also known as DCPP, is a chemical compound that belongs to the pyrazolo[3,4-d]pyrimidine family. It is a heterocyclic compound containing two chlorine atoms and a phenyl group. DCPP has been studied for its potential applications in pharmaceuticals and agrochemicals due to its unique chemical structure and biological activities. It has been found to exhibit antimicrobial, antiviral, and anticancer properties, making it a potential candidate for drug development. Additionally, DCPP has also been used as a building block in the synthesis of other complex organic compounds. However, due to its potentially hazardous nature, proper handling and safety precautions are necessary when working with DCPP in laboratory or industrial settings.

Upstream product

• 50270-27-4 2,4,6-trichloropyrimidine-5-carbaldehyde 
• 15973-83-8 4,6-dihydroxy-1-phenyl-pyrazolo-[3,4-d]pyrimidine 
• 15973-83-8 4,6-Dioxo-1-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo<3,4-d>pyrimidine 
• 59-88-1 phenylhydrazine hydrochloride 
• 15973-83-8 C₁₁H₈N₄O₂ 
• 100-63-0 phenylhydrazine 
• 5334-43-0 5-Amino-4-cyano-1-phenylpyrazole 
• 50427-77-5 5-amino-1-phenyl-1H-pyrazole-4-carboxamide 

Downstream Products

• 630107-80-1 Compound 4A 
• 1399821-48-7 2-((1-(2-chlorophenyl)-4-hydroxy-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-N-(4-isopropoxyphenyl)propanamide 
• 1351413-56-3 2-((4-hydroxy-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-amino)-N-(4-methoxyphenyl)propanamide 
• 1361961-39-8 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1361960-71-5 6-(4-fluorophenylsulfonyl)-N-(5-methyl-1H-pyrazol-3-yl)-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 142613-27-2 (RS)-2,7-dihydro-7-phenyl-2-(phenylmethyl)-5-chloro-3H-imidazo<1,2-c>pyrazolo<4,3-e>pyrimidine 
• 132537-80-5 -α-<1-<(1-phenyl-6-chloro-1H-pyrazolo<3,4-d>pyrimidin-4-yl)amino>ethyl>benzenemethanol 
• 132537-78-1 (S)-N-(1-methyl-2-phenylethyl)-1-phenyl-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 130023-98-2 1-Phenyl-4,6,7,8-tetrahydro-1H-imidazo<1,2-a>pyrazolo<3,4-d>pyrimidin-7-one 
• 130024-03-2 1-Phenyl-8-benzyl-4,6,7,8-tetrahydro-1H-imidazo<1,2-a>pyrazolo<3,4-d>pyrimidin-7-one 
• 130024-01-0 8-Butyl-1-phenyl-4,6,7,8-tetrahydro-1H-imidazo<1,2-a>pyrazolo<3,4-d>pyrimidin-7-one 
• 130024-08-7 Ethyl 6-chloro-1-phenyl-4,5-dihydro-1H-pyrazolo<3,4-d>pyrimidine-5-acetate 
• 130024-11-2 1-Phenyl-1,4,6,7,8,9-hexahydropyrazolo<3',4':4,5>pyrimido<2,1-c><1,2,4>triazin-7-one 
• 130024-13-4 6-Chloro-1-phenyl-4,5-dihydro-1H-pyrazolo<3,4-d>pyrimidin-5-acetamide 

Relevant articles and documents

COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF

The present invention provides a compound having a specific chemical structure and having PDE9A inhibitory activity, or a pharmaceutically acceptable salt thereof. The present invention provides a composition containing the compound or a pharmaceutically acceptable salt thereof. The present invention provides a pharmaceutical use, for treating or preventing PDE9A-related diseases, of the compound according to the present invention, a salt thereof, and a composition containing the compound or salt. The present invention also provides a method for treating or preventing PDE9A-related diseases, the method comprising administering an effective amount of the compound according to the present invention, a salt thereof, or a composition containing the compound or salt to a subject in need of treatment.

COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF

The present invention provides a compound having a specific chemical structure and having PDE9A inhibitory activity, or a pharmaceutically acceptable salt thereof. The present invention provides a composition containing the compound or a pharmaceutically acceptable salt thereof. The present invention provides a pharmaceutical use, for treating or preventing PDE9A-related diseases, of the compound according to the present invention, a salt thereof, and a composition containing the compound or salt. The present invention also provides a method for treating or preventing PDE9A-related diseases, the method comprising administering an effective amount of the compound according to the present invention, a salt thereof, or a composition containing the compound or salt to a subject in need of treatment.

Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design

A new series of phosphodiesterase-9 (PDE9) inhibitors that contain a scaffold of 6-amino-pyrazolopyrimidinone have been discovered by a combination of structure-based design and computational docking. This procedure significantly saved the load of chemical synthesis and is an effective method for the discovery of inhibitors. The best compound 28 has an IC50 of 21 nM and 3.3 μM, respectively, for PDE9 and PDE5 and about 3 orders of magnitude of selectivity against other PDE families. The crystal structure of the PDE9 catalytic domain in complex with 28 has been determined and shows a hydrogen bond between 28 and Tyr424. This hydrogen bond may account for the 860-fold selectivity of 28 against PDE1B, in comparison with about 30-fold selectivity of BAY73-6691. Thus, our studies suggest that Tyr424, a unique residue of PDE8 and PDE9, is a potential target for improvement of selectivity of PDE9 inhibitors.